Comparative Pharmacology
Head-to-head clinical analysis: CAPASTAT SULFATE versus NEOPASALATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPASTAT SULFATE versus NEOPASALATE.
CAPASTAT SULFATE vs NEOPASALATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Capastat sulfate (capreomycin) is a cyclic polypeptide antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, interfering with initiation and elongation steps.
Para-aminosalicylic acid (PAS) competitively inhibits the conversion of aminobenzoic acid to dihydrofolate, thereby inhibiting Mycobacterium tuberculosis growth.
15 mg/kg (max 1 g) intramuscularly daily for 60-120 days.
4-6 g orally twice daily; maximum 12 g/day.
None Documented
None Documented
3-6 hours; prolonged to 12-24 hours in renal impairment; negligible hepatic metabolism
Terminal elimination half-life is 2.5–4.5 hours in adults, prolonged in renal impairment.
Primarily renal (80-90% as unchanged drug via glomerular filtration); minor fecal (10-20%)
Primarily renal (≥80% as unchanged drug and acetylated metabolite); minor fecal elimination (<5%).
Category C
Category C
Antituberculosis Agent
Antituberculosis Agent